The Genesis Conference, which is organised by the ONE NUCLEUS cluster (London and Cambridge), and, this year, celebrates its tenth anniversary, is a key event in the life-sciences sector. For the fifth consecutive year, Genesis will give five innovative French companies the opportunity to showcase their services and expertise, thanks to the support provided by the French Trade Commission UBIFRANCE in London.
The companies taking part in the French Pavilion are as follows. Further details can be provided on request.
Founded in 1993, ALCIMED assists decision-makers in terms of their strategic development and their positioning. ALCIMED acts as the interface between science and business, and helps clients – be they sales and marketing directors, corporate-level directors, or R&D managers – to grasp new opportunities, adapt to potential threats such as changes in regulation, come up with novel solutions, and translate ideas into practice.
ALCIMED employs 180 highly skilled people across four countries and will open its London office in 2012.
For more information, please go to: www.alcimed.com
Aureus Pharma provides a range of scientific knowledge solutions enabling biopharmaceutical companies to better understand the chemical and biological space around major therapeutic targets and, therefore, to better identify drug profiles. Aureus Pharma’s information solutions streamline the discovery process for many of the world’s most successful biopharmaceutical companies and leading research institutions.
The new Aureus Sciences Web Portal will be released in 2011, which will allow professionals in the pharmaceutical and biotech sectors to access a collaborative network, as well as editorial content, and specific dashboards.
For more information, please go to: www.aureus-pharma.com
Bertin Pharma offers a comprehensive and integrated range of products and services throughout the drug-development value chain. The company was created out of a merger between four well-established French companies – Biotec Centre, Ellipse Pharmaceuticals, IDPS and SPI-Bio. Bertin Pharma now employs over 100 pharmacists, scientists and technicians.
Bertin Pharma positions itself as “an ideal partner for preclinical, clinical and pharmaceutical development, as well as bio-safety studies”. The company offers expertise, innovative technologies, dedicated technical platforms, environments with appropriate quality standards (GLP, GMP and GDP) and specific competencies applied to biologics.
For more information, please go to: www.bertin.fr
HISTALIM is a technical platform for histology, cytology and molecular biology, offering a large range of services addressing the pharmaceutical and CRO sectors.
HISTALIM is now embarking on its next stage of development, in the hope of becoming the reference platform for histology, cytology and molecular biology for every application type within the next five years. Its goal is also to become a key partner for method-designing and image-analysis applications in histotechnology.
For more information, please go to: www.histalim.com
Keyrus Biopharma is a European CRO offering a complete range of services from preclinical to post-marketing studies. Keyrus Biopharma divides its expertise into five main areas: clinical operations, biometry, medical writing, pharmacovigilance and quality assurance. With over 12 years’ experience in clinical trials, Keyrus Biopharma has worked with a number of major clients in the fields of medicine, nutrition, vaccines, biotechnology, medical devices and cosmetics.
A rapidly expanding company, Keyrus Biopharma plans to invest in the British market in the next two years in order to meet the demand of its clients.
For more information, please go to: www.keyrusbiopharma.com
About the French Trade Commission UBIFRANCE
The Trade Commission of the French Embassy in London promotes trade development between France and the UK by offering a range of services to French-based companies. The Consumer Goods and Healthcare Department organises B2B events in the form of conferences and networking opportunities, mainly in London.
Genesis will take place at the QEII Conference Centre in central London (England) on 9 December 2010. It will bring together professionals from across the biotechnology and life-sciences sectors.
For more information, please contact Ms Judith Arkle, Senior Trade Adviser in charge of healthcare and biotechnology at the French Trade Commission UBIFRANCE in London, or Ms Mary-Ann Williams, Press Officer.Ms Judith Arkle
Mary-Ann Williams | UBIFRANCE
COMPAMED 2016 connected medical devices and people
23.11.2016 | IVAM Fachverband für Mikrotechnik
Successfully transferring Industrie 4.0 into reality
21.11.2016 | Deutsches Forschungszentrum für Künstliche Intelligenz GmbH, DFKI
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering